AseptiScope Appoints Tom Watlington as Chief Commercial Officer in Preparation for the Launch of the Innovative DiskCover System™ for Stethoscope Decontamination

Share Article

In advance of the 2020 launch of its novel system to reduce stethoscope contamination, AseptiScope, Inc. is pleased to announce the appointment of Tom Watlington as Chief Commercial Officer. Tom, a highly regarded leader in the biotech start-up community and serial entrepreneur, has a proven track record of successfully forming healthcare organizations, building and revitalizing commercial operations, and forging pivotal strategic business alliances that substantially drove profits, efficiencies and growth.

News Image
Tom brings tremendous commercial expertise, passion, and demonstrated success in start-up device launches to the team. We remain extremely confident in our exceptional team as we introduce technology that will finally resolve an enormous patient safety concern.

In advance of the 2020 launch of its novel system to reduce stethoscope contamination, AseptiScope, Inc. is pleased to announce the appointment of Tom Watlington as Chief Commercial Officer. Tom, a highly regarded leader in the biotech start-up community and serial entrepreneur, has a proven track record of successfully forming healthcare organizations, building and revitalizing commercial operations, and forging pivotal strategic business alliances that substantially drove profits, efficiencies and growth. In addition to his leadership and strategic partnering while in the Diabetes Care arm of the biotech giant, Boehringer Mannheim, Tom led commercial operations at Biosite during which time he increased production, executed an unprecedented launch of the Triage BNP test and grew sales to $300M. He later led innovative startups such as Naviscan, Cuida Health and Sotera Wireless, and gained considerable experience in raising private capital and developing and commercializing complex medical technology. Tom joins an already impressive and growing executive team that includes experienced cross-functional leaders in healthcare, clinical and biotech experts, and a host of advisors working in unison to prepare the organization for next year’s DiskCover™ System launch.

“Tom brings tremendous commercial expertise, passion, and demonstrated success in start-up device launches to the team,” said Scott Mader, CEO and President of AseptiScope. “We remain extremely confident in our exceptional team as we introduce technology that will finally resolve an enormous patient safety concern.”

“It’s an exciting time to be part of AseptiScope and introducing a long-overdue solution to address a serious healthcare problem,” said Tom Watlington. “We are taking meaningful steps toward the DiskCover System’s launch, which will soon have a dramatic impact on reducing infectious disease transmissions and improving patient care.”

About AseptiScope, Inc.
AseptiScope is a privately funded San Diego, California based, clinical innovation company, formed in early 2016. The organization is founded and led by clinical innovation experts, leading medical researchers and practicing physicians. The AseptiScope mission is to design, develop, manufacture and commercialize novel solutions that ensure “Infection Protection for Clinician & Patient.” The company will introduce the first true and practical solution for the longstanding challenge of stethoscope contamination in early 2020: The AseptiScope DiskCover™ System. Visit http://www.aseptiscope.com for more information.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lauren Lehman
Visit website